A recent ruling by the U.S. Treasury Department scuttled a proposed and very large merger between two drug companies—the U.S.-based Pfizer Corporation and the Dublin-based Allergan. The proposed merger was motivated in part by expected tax savings that would have been realized by Pfizer moving its headquarters to Ireland after
